Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.73 |
| ▸ | RAB9A | P51151 | 5/20 | 0.73 |
| ▸ | CA1 | P00915 | 2/20 | 0.66 |
| ▸ | CA2 | P00918 | 2/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | PLK1 | P53350 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9584772 | 0.98 | NPC1 (0.71) | NPC1RAB9ACA1CA2NFKB1 | |
| SCHEMBL31493853 | 0.91 | NPC1 (0.69) | NPC1RAB9ACA1CA2NFKB1 | |
| SCHEMBL16301502 | 0.90 | NPC1 (0.79) | NPC1RAB9ACA1CA2NFKB1 | |
| SCHEMBL16685001 | 0.89 | NPC1 (0.83) | NPC1RAB9ACA1CA2NFKB1 | |
| SCHEMBL15923499 | 0.87 | NPC1 (0.85) | NPC1RAB9ACA1CA2SMN1; SMN2 | |
| SCHEMBL3861146 | 0.85 | MAOB (0.81) | NFKB1CYP1A2TSHRMAOBKMT2A | |
| SCHEMBL16677166 | 0.85 | NPC1 (0.61) | NPC1RAB9ACA1CA2NFKB1 | |
| SCHEMBL31493840 | 0.85 | NPC1 (0.61) | NPC1RAB9ACA1CA2NFKB1 | |
| SCHEMBL7558651 | 0.84 | SMYD3 (0.56) | NPC1RAB9ACA1CA2NFKB1 | |
| SCHEMBL9489987 | 0.84 | NPC1 (1.00) | NPC1RAB9ACA1CA2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119163-A | Low-hemolytic cationic lipid and application thereof | 郑州大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-118697890-A | High-concentration nanoparticle gel and preparation method thereof | 郑州大学 | 2024-09-27 | — | — | CN | disclosed |
| WO-2023102477-A1 | PERIPHERALLY AND LUMINALLY-RESTRICTED INHIBITORS OF THE SEROTONIN TRANSPORTER AS TREATMENTS FOR DISORDERS OF GASTROINTESTINAL MOTILITY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-06-08 | — | — | WO | disclosed |
| CN-114163547-B | Pharmaceutical composition for mild photothermal treatment of tumor as well as preparation method and application thereof | 中国药科大学 | 2023-05-30 | — | — | CN | disclosed |
| US-20220378936-A1 | DELIVERY SYSTEM COMPLEXES COMPRISING A PRECIPITATE OF AN ACTIVE AGENT AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2022-12-01 | — | — | US | disclosed |
| US-11510988-B2 | Targeting aminoacid lipids | MERCK PATENT GMBH (DE) | 2022-11-29 | — | — | US | disclosed |
| EP-4041314-A1 | DELIVERY SYSTEM COMPLEXES COMPRISING A PRECIPITATE OF AN ACTIVE AGENT AND METHODS OF USE | The University of North Carolina at Chapel Hill (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114746124-A | Delivery system complexes comprising active agent precipitates and methods of use | 北卡罗来纳-查佩尔山大学 | 2022-07-12 | — | — | CN | disclosed |
| CN-112390751-B | Toll-like receptor-7 small molecule inhibitor and preparation method thereof | 清华大学 | 2022-07-05 | — | — | CN | disclosed |
| CN-114163547-A | Pharmaceutical composition for mild photothermal treatment of tumors and preparation method and application thereof | 中国药科大学 | 2022-03-11 | — | — | CN | disclosed |
| CN-104168888-A | Targeting aminoacid lipids | MERCK PATENT GMBH | 2014-11-26 | — | — | CN | disclosed |
| CN-104168887-A | Amino acid lipids | MERCK PATENT GMBH | 2014-11-26 | — | — | CN | disclosed |
| WO-2013135360-A1 | AMINOACID LIPIDS | MERCK PATENT GMBH (DE) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013135359-A1 | TARGETING AMINOACID LIPIDS | MERCK PATENT GMBH (DE) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013135360-A1 | AMINOACID LIPIDS | MERCK PATENT GMBH (DE) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013135359-A1 | TARGETING AMINOACID LIPIDS | MERCK PATENT GMBH (DE) | 2013-09-19 | — | — | WO | disclosed |
| EP-0922050-B1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-0922050-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-06-16 | — | — | EP | disclosed |
| US-5750510-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1997042205-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378936-A1 | DELIVERY SYSTEM COMPLEXES COMPRISING A PRECIPITATE OF AN ACTIVE AGENT AND METHODS OF USE | SLC46A1, DPYD, FOLR2 | NPC1 3482/4885RAB9A 2284/4885CA1 201/4885 |
| US-11510988-B2 | Targeting aminoacid lipids | PTDSS2, DNPEP, FABP1 | NPC1 495/4885RAB9A 2079/4885CA1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.